Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib

This report discusses a case of a patient with alopecia areata who did not respond to traditional Chinese medicine or ritlecitinib, a standard therapy. The patient showed significant recovery after being treated with upadacitinib, with all symptoms normalizing by the 24-week follow-up. The study highlights the effectiveness of upadacitinib and the importance of JAK1-mediated pathways in treating alopecia areata, suggesting that personalized treatment strategies could be beneficial for patients with this condition.